

of vaccines, and analyze the incidence of COVID-19 infection based on different vaccination approaches. This information may guide future vaccination strategies or COVID treatments. The vaccination status of recipients may also be useful for risk adjustment in the annual transplant center-specific analysis. For example, CDC advisors could potentially use COVID-19 vaccination data on blood stem cell transplant recipients to make informed decisions regarding whether to issue any recommendations for this medically vulnerable population. The data collected under this extension request could help answer these and other questions.

The additional COVID-19 vaccine questions capture basic information on vaccination status, vaccine manufacturer/type, dose(s) given, and date(s) received. Patients who need a blood stem cell transplant are typically aware of their COVID-19 risk and

vaccination status, and the information is also found on the vaccine cards carried by most recipients. Questions about vaccination status will likely become universal at transplant center intake for the next 12 months or more. For these reasons, HRSA believes the data will be readily available to data professionals working at transplant centers via the medical record. To reduce burden, an “unknown” option has been included for scenarios where the data cannot be located, and a “date estimated” checkbox has been included when the exact date of vaccination is not known. Although these questions are anticipated to be asked over the next 12 months and then removed, other COVID-19 related questions may be requested for inclusion on these forms in the future given the rapid evolution of COVID-19 and its impact on immunocompromised patients, availability of new vaccines, and

continual changes in vaccination recommendations.

Likely Respondents: Transplant Centers.

Burden Statement: Burden in this context means the time expended by persons to generate, maintain, retain, disclose or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install, and utilize technology and systems for the purpose of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information, and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below.

Form name	Number of respondents ¹	Number of responses per respondent	Total responses	Average burden per response (in hours)	Total burden hours
Baseline Pre-Transplant Essential Data (TED)	200	48	9,600	² 0.70	6,720
Disease Classification	200	48	9,600	³ 0.43	4,160
Product Form (includes Infusion, HLA, and Infectious Disease Marker inserts)	200	45	9,000	1.00	9,000
100-day Post-TED	200	48	9,600	0.88	8,448
6 month Post-TED	200	43	8,600	0.85	7,310
1 year Post-TED	200	40	8,000	0.65	5,200
2 year Post-TED	200	34	6,800	0.65	4,420
3+ years Post-TED	200	172	34,400	⁴ 0.52	17,773
Total	200	95,600	63,031

¹ The total of 200 is the number of centers completing the form; the same group will complete all of the forms.

² The decimal is rounded up, and the actual number is .683333333.

³ The decimal is rounded down, and the actual number is .433333333.

⁴ The decimal is rounded up, and the actual number is .516667.

HRSA specifically requests comments on (1) the necessity and utility of the proposed information collection for the proper performance of the agency's functions, (2) the accuracy of the estimated burden, (3) ways to enhance the quality, utility, and clarity of the information to be collected, and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Maria G. Button,

Director, Executive Secretariat.

[FR Doc. 2022-02318 Filed 2-3-22; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Request for Information: Regarding a Revision to U.S. Public Health Service Guideline: Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection

AGENCY: Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

ACTION: Request for information.

SUMMARY: The Office of the Assistant Secretary for Health in the Department of Health and Human Services (HHS) seeks public comment regarding a proposed revision to the 2020 PHS Guideline Assessing Solid Organ Donors

and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection (1). The Organ Procurement and Transplantation Network (OPTN) implemented a policy change related to organ transplant candidate assessment and testing on March 1, 2021, to align OPTN policy with the new Guideline recommendations (2). Previous PHS Guideline recommendations did not include a specific timeframe during which pre-transplant testing for HIV, HBV, and HCV infections among organ transplant candidates should occur. In order to more accurately assess pre-transplant infection status and to enable the investigation of possible solid organ donor transmission of infection, the 2020 Guideline specified that pre-transplant HIV, HBV, and HCV testing of transplant candidates should occur during hospital admission for transplant

surgery but prior to the implantation of the organ. In May 2021, HHS reviewed communications from members of the public to the OPTN, outlining concerns that the additional amount of blood drawn for infectious disease testing (when added to the relatively large amount of blood required for immediate preoperative laboratory testing) during the admission for transplantation poses potential risks for some pediatric organ transplant candidates. Potential risks due to blood volume loss include those related to preoperative low body weight (and low blood volume), anemia, or exacerbation of underlying co-morbid conditions. HHS conducted a review of the most recent HIV, HBV, and HCV surveillance data in the United States as stratified by age group. Additionally, HHS engaged with relevant stakeholders during May–November 2021, to understand implications of policy changes on organ transplantation and organ utilization. In December 2021, findings from these analyses were presented to the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA). The committee considered whether a revision to the Guideline recommendation pertaining to pre-transplant testing of candidates ≤ 10 years of age is warranted. Based on feedback from the ACBTSA and analyses specified above, HHS is proposing changes pertinent to the timing of pre-transplant testing for candidates ≤ 10 years of age. HHS is asking respondents to review the proposed revision to the current Guideline (listed in the Supplementary Information section of this notice) and provide assessments on updating the Guideline, whether this change is achievable in the clinical setting, or if there are potential barriers to implementation. In addition, impact on organ allocation and utilization should be considered. Other comments pertinent to this proposed revision are welcome.

DATES: To be assured consideration, comments must be received at the address provided below no later than 5:00 p.m. ET on March 7, 2022.

ADDRESSES: Electronic responses are strongly preferred and may be addressed to ACBTSA@hhs.gov. Please include in the subject line of the email: ACBTSA–RFI.

FOR FURTHER INFORMATION CONTACT: Mr. James Berger, Designated Federal Official, Office of Infectious Disease and HIV/AIDS Policy, 202–795–7608.

SUPPLEMENTARY INFORMATION:

Background: Since the emergence of the human immunodeficiency virus (HIV) epidemic in the 1980s, the U.S. Public

Health Service (PHS) has made recommendations to reduce the risk of HIV transmission associated with organ transplantation (3, 4). Historically, recommendations included identifying risk factors among organ donors associated with HIV infection to minimize risk of potential transmission to recipients. Recommendations also included laboratory screening of donors using anti-HIV antibody testing, with additional testing recommendations added as technologies such as nucleic acid testing (NAT) were developed. In 2013, based on donor-derived transmission events and reports of poor recipient outcomes from hepatitis B virus (HBV) and hepatitis C virus (HCV) transmission, the PHS released a revised guideline. The 2013 Guideline added organ donor screening recommendations for HBV (hepatitis B surface antigen [HBsAg] and total antibody to hepatitis B core antigen [total anti-HBc]) and HCV (antibody to hepatitis C [anti-HCV] and HCV RNA by NAT), in addition to HIV, to reduce the risk of unintended transmission through transplantation (5). This revised Guideline was enhanced by recommending specific recipient informed consent and post-transplant recipient monitoring for evidence of possible disease transmission.

In 2020, the Guideline was updated to reflect changes in the epidemiology of HIV, HBV, and HCV infections, advances in testing, and the widespread availability of highly effective (for HIV and HBV) and curative (for HCV) treatment. In addition to several other updated recommendations, the 2020 Guideline specified that all transplant candidates should be tested prior to surgery for HIV, HBV, and HCV infections, with testing to occur during hospital admission for transplant but before transplantation (1). This recommendation was implemented in order to more accurately assess pre-transplant infection status and to enable the investigation of whether infectious disease transmission may have occurred through transplantation. Based on the feedback from members of the public that this requirement for repeat screening at the time of transplantation might pose potential harm to some pediatric patients due to blood volume loss, HHS (including CDC and HRSA) conducted additional analyses of surveillance data. Additionally, CDC and HRSA also participated in a work group convened by the OPTN and which included members of the OPTN Disease Transmission Advisory Committee and Pediatric Committee.

CDC surveillance data for the years 2015–2019 pertaining to incident HIV

infections among pediatric populations in the United States were reviewed. Briefly, 524 children < 13 years of age in the United States and 6 U.S. territories and freely associated states received a new diagnosis of HIV infection from 2015–2019. Overall, 181 (35%) of these 524 children received their diagnosis of HIV infection between 0–5 months of age; an additional 23 (4%) were diagnosed between 6–11 months of age. With effective perinatal elimination efforts, prevalence and incidence of HIV infection in children < 13 years of age in the United States have been steadily decreasing (6). Children < 13 years of age are among the lowest risk group for new HIV infections in the United States. Estimated prevalence of HIV infection in children < 13 years of age in the United States is $< 2,000$; incidence in this age group is < 100 cases per year, and most of these are perinatally acquired (6). With perinatal testing and clinical follow-up of exposed children, it is unlikely that a transplant candidate ≤ 10 years of age would have an undiagnosed HIV infection at the time of organ transplantation.

CDC surveillance data for 2019 pertaining to incident HBV and HCV infections among pediatric populations in the United States were also reviewed. Incident HBV and HCV infections are similarly low among children in the United States. The rate of acute HBV infection in persons < 20 years in the United States was 0.0 per 100,000 population as of 2019 (7). Additionally, more than 90% of 2-year-olds and adolescents in the United States have been vaccinated against HBV (8, 9). The rate of acute HCV infection in persons < 20 years in the United States was 0.1 per 100,000 population as of 2019 (7). Perinatal exposure is the most common mode of transmission for HCV infection in children.

In December 2021, HHS convened the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) to receive expert input on whether, and if so, how, the current PHS Guideline recommendation pertaining to pre-transplant testing of pediatric candidates should be revised (<https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2021-12-01/index.html>). Additionally, HHS solicited input from this committee on the specific question as to whether available data support exempting solid organ transplant candidates who are ≤ 10 years of age at the time of transplant (and who have received postnatal infectious disease testing) from the recommendation for HIV, HBV, and HCV testing during hospital admission

for transplant but prior to anastomosis of the first organ. The committee voted unanimously in favor of the change.

Potential revision to the 2020 Guideline: HHS has reviewed the ACBTSA recommendations and other available information and is considering the following revision to current recommendations in the 2020 Guideline.

Exempt solid organ transplant candidates who are ≤ 10 years of age at the time of transplant (and who have received postnatal infectious disease testing) from the recommendation for HIV, hepatitis B virus, and hepatitis C virus testing during the hospital admission for transplant but prior to anastomosis of the first organ.

HHS is not considering changes to any other 2020 Guideline recommendations. We seek informed feedback regarding this proposed change to the recommendations in the 2020 Guideline.

Dated: January 25, 2022.

James J. Berger,

Designated Federal Officer, Advisory Committee on Blood and Tissue Safety and Availability, Office of Infectious Disease and HIV/AIDS Policy.

Footnotes

1. Jones JM, Kracalik I, Levi ME, et al. Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection—U.S. Public Health Service Guideline, 2020. *MMWR Recomm Rep* 2020;69(No. RR-4):1–16. DOI: <http://dx.doi.org/10.15585/mmwr.rr6904a1>.
2. OPTN Policy 15.2: Candidate Pre-Transplant Infectious Disease Reporting and Testing Requirements. Available: <https://optn.transplant.hrsa.gov/media/eavh5bf3/optn-policies-effective-as-of-dec-6-2021-e-signature.pdf>.
3. CDC. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. Centers for Disease Control and Prevention. *MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control*. 1994;43(RR-8):1–17.
4. CDC. Testing donors of organs, tissues, and semen for antibody to human T-lymphotropic virus type III/lymphadenopathy-associated virus. *MMWR Morbidity and mortality weekly report*. 1985;34(20):294.

5. Seem DL, Lee I, Umscheid CA, Kuehnert MJ. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. *Public health reports (Washington, DC: 1974)*. 2013;128(4):247–343.
6. Centers for Disease Control and Prevention. *HIV Surveillance Report, 2019*; vol.32. <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published May 2021.
7. Centers for Disease Control and Prevention. 2019 Viral Hepatitis Surveillance Report. <https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm>. Published July 2021.
8. FastStats—Immunization ([cdc.gov](https://www.cdc.gov/nchs/fastats/immunize.htm)): <https://www.cdc.gov/nchs/fastats/immunize.htm>.
9. Elam-Evans LD, Yankey D, Singleton JA, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years—United States, 2019. *MMWR Morb Mortal Wkly Rep* 2020;69:1109–1116. DOI: <http://dx.doi.org/10.15585/mmwr.mm6933a1>.

[FR Doc. 2022–02389 Filed 2–3–22; 8:45 am]

BILLING CODE 4150–28–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group; Aging Systems and Geriatrics Study Section.

Date: March 3–4, 2022.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Inese Z. Beitins, MD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6152, MSC 7892, Bethesda, MD 20892, 301–435–1034, beitinsi@csr.nih.gov.

Name of Committee: Healthcare Delivery and Methodologies Integrated Review Group; Organization and Delivery of Health Services Study Section.

Date: March 3–4, 2022.

Time: 9:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Catherine Haderler Maulsby, MPH, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 435–1266, maulsbych@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR–20–117: Maximizing Investigators' Research Award (MIRA) for Early Stage Investigators (R35—Clinical Trial Optional).

Date: March 8–9, 2022.

Time: 9:00 a.m. to 8:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Anita Szajek, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–827–6276, anita.szajek@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Drug Discovery Involving the Nervous System.

Date: March 8–9, 2022.

Time: 9:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Lai Yee Leung, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1011D, Bethesda, MD 20892, (301) 435–1042, leungl2@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Biomaterials, Delivery, and Nanotechnology.

Date: March 10–11, 2022.

Time: 9:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: David Filpula, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6181,